A. G. Zhukov
Research Subjects
A. G. Zhukov has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Pervin A. Zeynalova
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Clinical Hospital "Lapino" of the "Mother and Child" Group of Companies
14 shared publications - Yulia E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
14 shared publications Ю. Е. Рябухина
Клинический госпиталь «Лапино» группы компаний «Мать и дитя
14 shared publications- Firuza М. Abbasbeyli
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
12 shared publications - O. L. Timofeeva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
12 shared publications - Timur Teimurazovich Valiev
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
10 shared publications
Latest Publications
- Open Access
- 24 September 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (3) , 93-98
Splenic marginal zone lymphoma: management specifics. Clinical observation
Despite having common histological and immunophenotypic characteristics with other marginal zone lymphomas, splenic marginal zone lymphoma (SMZL) has distinctive clinical and biological features. The main indications for therapy of this disease (of primarily indolent progression) are progressive splenomegaly and/or progressive cytopenia. Current clinical management guidelines do not conclusively point to advantages of one certain therapy, and there is no universal algorithm of management of patients with newly diagnosed SMZL manifesting through progressive splenomegaly. Therefore, determination of indications for surgical treatment is an important problem. A clinical observation of a female patient with newly diagnosed advanced SMZL is presented. Due to progressive splenomegaly and hypersplenism symptoms, the patient underwent splenectomy. Personalized multidisciplinary approach allowed to relieve hypersplenism symptoms as quickly as possible, and the absence of postoperative complications with indolent disease progression significantly increased the patient’s quality of life and allowed to continue dynamic observation.
- 24 September 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (3) , 93-98
Open AccessSplenic marginal zone lymphoma: management specifics. Clinical observation
Despite having common histological and immunophenotypic characteristics with other marginal zone lymphomas, splenic marginal zone lymphoma (SMZL) has distinctive clinical and biological features. The main indications for therapy of this disease (of primarily indolent progression) are progressive splenomegaly and/or progressive cytopenia. Current clinical management guidelines do not conclusively point to advantages of one certain therapy, and there is no universal algorithm of management of patients with newly diagnosed SMZL manifesting through progressive splenomegaly. Therefore, determination of indications for surgical treatment is an important problem. A clinical observation of a female patient with newly diagnosed advanced SMZL is presented. Due to progressive splenomegaly and hypersplenism symptoms, the patient underwent splenectomy. Personalized multidisciplinary approach allowed to relieve hypersplenism symptoms as quickly as possible, and the absence of postoperative complications with indolent disease progression significantly increased the patient’s quality of life and allowed to continue dynamic observation.
- Open Access
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 55-64
Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital
Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.
- 14 June 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (2) , 55-64
Open AccessPolatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital
Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.
- Open Access
- 25 March 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (1) , 63-70
Use of daratumumab in combination with lenalidomide and dexamethasone (D-Rd regimen) in therapy of elderly patients with newly diagnosed multiple myeloma with high-risk cytogenetics. Clinical observation
Multiple myeloma (MM) is a B cell lymphoproliferative disease characterized by clonal proliferation of plasma cells and heterogenous progression. Successes in MM therapy are in large part based on the study of molecular and genetic features of disease pathogenesis and identification of high-risk chromosomal abnormalities determining prognosis and antitumor response. Elderly patients with newly diagnosed MM with high-risk cytogenetics who are not candidates for autologous stem cell transplantation should receive programs of antitumor therapy which increase progression-free survival and overall survival with satisfactory tolerability and minimal toxicity. Use of monoclonal antibodies in triplets at early stages allow to achieve deeper antitumor response, the absence of minimal residual disease in a greater number of observations, and improve survival in all patient subgroups.A clinical observation of a 75-year-old female patient with newly diagnosed MM with high-risk cytogenetics and multiple bone plasmacytomas with massive extraosseous components is presented. During D-Rd regimen therapy, after 8 daratumumab administrations very good partial remission was achieved which has been maintained for 20 months. Significant improvement in quality of life with satisfactory treatment tolerability and absence of adverse events are observed
- 25 March 2024
- Published by Publishing House ABV Press in MD-Onco
- Vol. 4 (1) , 63-70
Open AccessUse of daratumumab in combination with lenalidomide and dexamethasone (D-Rd regimen) in therapy of elderly patients with newly diagnosed multiple myeloma with high-risk cytogenetics. Clinical observation
Multiple myeloma (MM) is a B cell lymphoproliferative disease characterized by clonal proliferation of plasma cells and heterogenous progression. Successes in MM therapy are in large part based on the study of molecular and genetic features of disease pathogenesis and identification of high-risk chromosomal abnormalities determining prognosis and antitumor response. Elderly patients with newly diagnosed MM with high-risk cytogenetics who are not candidates for autologous stem cell transplantation should receive programs of antitumor therapy which increase progression-free survival and overall survival with satisfactory tolerability and minimal toxicity. Use of monoclonal antibodies in triplets at early stages allow to achieve deeper antitumor response, the absence of minimal residual disease in a greater number of observations, and improve survival in all patient subgroups.A clinical observation of a 75-year-old female patient with newly diagnosed MM with high-risk cytogenetics and multiple bone plasmacytomas with massive extraosseous components is presented. During D-Rd regimen therapy, after 8 daratumumab administrations very good partial remission was achieved which has been maintained for 20 months. Significant improvement in quality of life with satisfactory treatment tolerability and absence of adverse events are observed
- Open Access
- 8 December 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (4) , 90-103
Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
Multiple myeloma is a malignant tumor characterized by the proliferation of clonal plasma cells and currently remains an incurable disease, despite advances in therapy. Resistance and development of double refractoriness represent a significant problem, worsening the prognosis. To overcome double refractoriness, new proteasome inhibitors carfilzomib and ixazomib, the 3rd generation immunomodulator pomalidomide and monoclonal antibodies daratumumab, elotuzumab and isatuximab are used. Based on randomized phase III ICARIA-MM and IKEMA studies results, which demonstrated, along with a manageable safety profile, advantages in increasing the antitumor response depth, the rate of achieving negative minimal residual disease status and survival in all subgroups of patients with refractory/relapsed multiple myeloma, isatuximab is used in IsaPd (isatuximab, pomalidomide, dexamethasone) and IsaKd (isatuximab, carfilzomib, dexamethasone) combination. This article discusses the clinical pharmacology of isatuximab. The results of studies demonstrating the effectiveness and safety of antitumor therapy regimens including isatuximab, which made it possible to use it in clinical practice, are presented. We present a case report of a patient with refractory/relapsed multiple myeloma who received 3 lines of antitumor treatment, including class 2 proteasome inhibitors, lenalidomide and the monoclonal antibody elotuzumab. After 3 cycles of IsaPd (8 injections of isatuximab), partial remission and pain relief were recorded. The achieved antitumor effect, along with the absence of significant adverse events, facilitated the continuation of therapy at recommended doses.
- 8 December 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (4) , 90-103
Open AccessIsatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
Multiple myeloma is a malignant tumor characterized by the proliferation of clonal plasma cells and currently remains an incurable disease, despite advances in therapy. Resistance and development of double refractoriness represent a significant problem, worsening the prognosis. To overcome double refractoriness, new proteasome inhibitors carfilzomib and ixazomib, the 3rd generation immunomodulator pomalidomide and monoclonal antibodies daratumumab, elotuzumab and isatuximab are used. Based on randomized phase III ICARIA-MM and IKEMA studies results, which demonstrated, along with a manageable safety profile, advantages in increasing the antitumor response depth, the rate of achieving negative minimal residual disease status and survival in all subgroups of patients with refractory/relapsed multiple myeloma, isatuximab is used in IsaPd (isatuximab, pomalidomide, dexamethasone) and IsaKd (isatuximab, carfilzomib, dexamethasone) combination. This article discusses the clinical pharmacology of isatuximab. The results of studies demonstrating the effectiveness and safety of antitumor therapy regimens including isatuximab, which made it possible to use it in clinical practice, are presented. We present a case report of a patient with refractory/relapsed multiple myeloma who received 3 lines of antitumor treatment, including class 2 proteasome inhibitors, lenalidomide and the monoclonal antibody elotuzumab. After 3 cycles of IsaPd (8 injections of isatuximab), partial remission and pain relief were recorded. The achieved antitumor effect, along with the absence of significant adverse events, facilitated the continuation of therapy at recommended doses.
- Open Access
- 6 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 16-27
Use of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation
Study of the molecular pathogenesis of multiple myeloma led to development and introduction of antitumor agents with new mechanisms of action and their combinations into clinical practice. According to several trials, use of anti-CD38 monoclonal antibody daratumumab as part of triplet therapies at an early stage leads to deep and long-term antitumor response, achievement of MRD-negative status, and, as a result, increased survival and improved prognosis in all patient subgroups. High effectiveness of daratumumab subcutaneous formulation close to intravenous formulation has favorable safety profile, short administration time and low rate of infusion reactions which improves patients’ quality of life, affects their treatment compliance, and decreases healthcare costs.We present a clinical observation of a 60-year-old patient with newly diagnosed multiple myeloma who previously underwent treatment for another lymphoproliferative disorder which included autologous hematopoietic stem cell transplantation leading to complete and long-term remission. After 9 intravenous daratumumab infusions (with recommended dose of 16 mg/kg) in accordance to the D-Rd regimen, evaluation of antitumor effect and consideration of socially active lifestyle of the patient, daratumumab formulation for intravenous administration was replaced with subcutaneous formulation of fixed dose 1800 mg. Further deepening of the antitumor response was observed along with manageable safety profile and absence of significant adverse events which allowed to maintain intercourse intervals and improve the patient’s quality of life.
- 6 December 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (4) , 16-27
Open AccessUse of daratumumab drug formulation for subcutaneous administration in multiple myeloma therapy: Literature review and clinical observation
Study of the molecular pathogenesis of multiple myeloma led to development and introduction of antitumor agents with new mechanisms of action and their combinations into clinical practice. According to several trials, use of anti-CD38 monoclonal antibody daratumumab as part of triplet therapies at an early stage leads to deep and long-term antitumor response, achievement of MRD-negative status, and, as a result, increased survival and improved prognosis in all patient subgroups. High effectiveness of daratumumab subcutaneous formulation close to intravenous formulation has favorable safety profile, short administration time and low rate of infusion reactions which improves patients’ quality of life, affects their treatment compliance, and decreases healthcare costs.We present a clinical observation of a 60-year-old patient with newly diagnosed multiple myeloma who previously underwent treatment for another lymphoproliferative disorder which included autologous hematopoietic stem cell transplantation leading to complete and long-term remission. After 9 intravenous daratumumab infusions (with recommended dose of 16 mg/kg) in accordance to the D-Rd regimen, evaluation of antitumor effect and consideration of socially active lifestyle of the patient, daratumumab formulation for intravenous administration was replaced with subcutaneous formulation of fixed dose 1800 mg. Further deepening of the antitumor response was observed along with manageable safety profile and absence of significant adverse events which allowed to maintain intercourse intervals and improve the patient’s quality of life.
- Open Access
- 19 September 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (3) , 18-28
Ibrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation
Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder which despite achieved successes in therapy is characterized by recurrences and refractoriness. Study of molecular biology allowed to use targeted drugs, in particular ibrutinib which acts through suppression of B cell receptor signaling pathway by inhibiting Bruton’s tyrosine kinase. In several large trials, ibrutinib demonstrated its effectiveness and manageable toxicity profile both in patients with newly diagnosed and recurrent/refractory WM. A clinical observation of a patient with WM is presented. Due to minimal response during previous treatment, the patient currently is undergoing monotherapy with ibrutinib with positive antitumor effect, satisfactory tolerability, and absence of significant adverse events. The effect of ibrutinib on humoral immunity during the follow up period was evaluated.
- 19 September 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (3) , 18-28
Open AccessIbrutinib in therapy of Waldenstrom’s macroglobulinemia: literature review and clinical observation
Waldenstrom’s macroglobulinemia (WM) is an indolent B-cell lymphoproliferative disorder which despite achieved successes in therapy is characterized by recurrences and refractoriness. Study of molecular biology allowed to use targeted drugs, in particular ibrutinib which acts through suppression of B cell receptor signaling pathway by inhibiting Bruton’s tyrosine kinase. In several large trials, ibrutinib demonstrated its effectiveness and manageable toxicity profile both in patients with newly diagnosed and recurrent/refractory WM. A clinical observation of a patient with WM is presented. Due to minimal response during previous treatment, the patient currently is undergoing monotherapy with ibrutinib with positive antitumor effect, satisfactory tolerability, and absence of significant adverse events. The effect of ibrutinib on humoral immunity during the follow up period was evaluated.
- Open Access
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
An integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- 11 September 2023
- Published by Publishing House ABV Press in Oncohematology
- Vol. 18 (3) , 35-43
Open AccessAn integrated treatment approach in patient with metastatic colorectal cancer and concomitant late cardiovascular complications of chemoradiotherapy for Hodgkin’s lymphoma. Clinical case
The high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular the high efficacy of the currently used combined chemoradiotherapy for Hodgkin’s lymphoma not only significantly increased overall survival, but also made it possible for most patients to achieve the same quality of life as in a healthy population. at the same time, the problem of identifying late treatment complications, in particular cardiovascular diseases, remains an urgent problem, the timely diagnosis of which is an important task. the development of a second malignant neoplasm and the appointment of drug antitumor therapy with cardiotoxic agents necessitate a multidisciplinary approach. In the presented clinical observation, such tactics of patient management made it possible not only to timely identify late cardiovascular complications of Hodgkin’s lymphoma chemoradiotherapy, but also to conduct treatment for the second malignant disease with cardiotoxic agents with a positive antitumor effect.
- Open Access
- 22 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 41-47
Integrative approach to diagnosis of lymphoproliferative disease during long-term Sjogren’s disease. Clinical observation
During long-term autoimmune processes, most commonly in patients with Sjogren’s disease (SD), lymphoproliferative disorders (LPD) can develop. The risk of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) with involvement of parotid salivary glands is increased 1,000-fold compared to other immunomorphological variants. Some studies show that the main factors predisposing patients with SD to LPD are long-term enlargement of parotid salivary glands, generalized lymphadenopathy, cryoglobulinemic purpura. Application of an integrative approach to LDP diagnosis in patients with SD, identification of high-risk group for this malignant neoplasm promote its early detection.A clinical observation of a female patients with long-term SD which was diagnosed along with MALT lymphoma using an integrative approach to diagnosis of both diseases is presented.
- 22 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 41-47
Open AccessIntegrative approach to diagnosis of lymphoproliferative disease during long-term Sjogren’s disease. Clinical observation
During long-term autoimmune processes, most commonly in patients with Sjogren’s disease (SD), lymphoproliferative disorders (LPD) can develop. The risk of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) with involvement of parotid salivary glands is increased 1,000-fold compared to other immunomorphological variants. Some studies show that the main factors predisposing patients with SD to LPD are long-term enlargement of parotid salivary glands, generalized lymphadenopathy, cryoglobulinemic purpura. Application of an integrative approach to LDP diagnosis in patients with SD, identification of high-risk group for this malignant neoplasm promote its early detection.A clinical observation of a female patients with long-term SD which was diagnosed along with MALT lymphoma using an integrative approach to diagnosis of both diseases is presented.
- Open Access
- 20 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 27-34
Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation
Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.
- 20 May 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (2) , 27-34
Open AccessUse of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation
Chronic pain syndrome developing in patients with oncological diseases significantly decreases their quality of life which makes effective integrative analgetic therapy a pressing issue. Currently, drugs of various pharmaceutical groups are used for pain management and administered subsequentially in accordance with the pain intensity visual analogue scale. For moderate and severe pain syndrome, opioid analgesics are used which have side effects limiting their use in some cases. Trials showed that new highly specific μ1-opioid receptor agonist tafalgin is characterized by high bioavailability, fast absorption, biotransformation, absence of accumulation which makes its safety profile favorable. Pronounced analgesic effect of tafalgin, as well as ease of administration and absence of significant adverse events, allow to significantly improve the quality of life of patients with chronic pain syndrome.
- Open Access
- 15 March 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (1) , 53-60
Use of obinutuzumab in therapy of patients with newly diagnosed follicular lymphoma. Experience of the Oncohematology Division of the Clinical Hospital “Lapino”
Follicular lymphoma (FL) is the most common indolent form of lymphoma and characterized by recurrent course and heterogenous clinical signs. Selection of treatment program for patients with newly diagnosed or recurrent FL is based primarily on the size of the tumor. While use of rituximab-containing regimens led to increased progression-free survival, in some cases tumors are refractory to rituximab. Understanding of molecular mechanisms of FL pathogenesis and action of anti-CD20 monoclonal antibodies allowed to develop new drugs with several advantages compared to rituximab. According to the data of large randomized trials, use of glycoengineered monoclonal anti-CD20 type II antibody obinutuzumab in combination with chemotherapy in patients with FL has manageable toxicity profile and longer progression-free survival and event-free survival compared to use of rituximab.
- 15 March 2023
- Published by Publishing House ABV Press in MD-Onco
- Vol. 3 (1) , 53-60
Open AccessUse of obinutuzumab in therapy of patients with newly diagnosed follicular lymphoma. Experience of the Oncohematology Division of the Clinical Hospital “Lapino”
Follicular lymphoma (FL) is the most common indolent form of lymphoma and characterized by recurrent course and heterogenous clinical signs. Selection of treatment program for patients with newly diagnosed or recurrent FL is based primarily on the size of the tumor. While use of rituximab-containing regimens led to increased progression-free survival, in some cases tumors are refractory to rituximab. Understanding of molecular mechanisms of FL pathogenesis and action of anti-CD20 monoclonal antibodies allowed to develop new drugs with several advantages compared to rituximab. According to the data of large randomized trials, use of glycoengineered monoclonal anti-CD20 type II antibody obinutuzumab in combination with chemotherapy in patients with FL has manageable toxicity profile and longer progression-free survival and event-free survival compared to use of rituximab.